47 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Diarylpyrazole compound, composition comprising same, and use thereof
Shenzhen Targetrx
METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A PD-1 BINDING ANTAGONIST
Hoffmann-La Roche
ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Sichuan Kelun-Biotech Biopharmaceutical
Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors
University of Utah
Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
Jazz Pharmaceuticals Ireland
Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
Hanmi Pharm.
Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
Korea Institute of Science and Technology
1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
Sabila Biosciences
Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
Korea Institute of Science and Technology
Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases
Hanmi Pharm.
3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
St. Chuan University
Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
Hanmi Pharm.
Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents.
Korea Institute of Science and Technology
Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases
Hanmi Pharm.
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
Boehringer Ingelheim International
Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
Boehringer Ingelheim International
Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Shanghai Institute of Pharmaceutical Industry
Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
Boehringer Ingelheim International
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
Amgen
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
The Institute of Cancer Research
Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors.
Novartis
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Plexxikon
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
Cancer Research Uk Centre For Cancer Therapeutics